Bio-Rad to Sell $300M in Senior Notes | GenomeWeb

NEW YORK (GenomeWeb News) – Bio-Rad Laboratories said today that it will raise $300 million through the sale of senior notes through a private offering.

The $300 million, which the company plans to use for general corporate purposes, working capital, and potentially for acquisitions, is an increase of $50 million over what the company said on Monday that it planned to receive from the sale.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.